Lilly's breast cancer drug combination succeeds in key study

(Reuters) - U.S. drugmaker Eli Lilly and Co said on Monday a combination of its experimental breast cancer drug and chemotherapy slowed disease progression in patients who had relapsed or did not derive enough benefit from prior treatment.